High postpartum maternal depression, stress, and morning cortisol concentration significantly decrease Shannon’s Entropy in infant stool. by Johanna R. Jahnke (10833803)

MAF1 protein expression is significantly decreased in luminal, HER2-positive, and TNBC breast cancer subtypes. by Stephanie Cabarcas-Petroski (9631636)

Subjects:

Transcriptionally-inferred PI3K pathway activation and breast tumor stemness/grade exhibit significant, positive association. by Ralitsa R. Madsen (11681590)

Metadata supporting the published article: Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer by Olga Kantor (9119030)

KCNK1 overexpression is significantly associated with breast cancer cells invasion and metastasis markers. by Xiangchan Hou (18864991)

Subjects:

Variants of uncertain significance. by Ghada Al-Kafaji (12054792)

Subjects:

Expression and clinical significance of PFKP in breast cancer. by Danna Yeerken (8911448)

Texture features with statistically significant differences between HER2 2+ positive and negative patients for subtraction images. by Lirong Song (458651)

A 71-year-old woman with true-positive bone metastases. by Jeanette Ansholm Hansen (11726084)

A 54-year-old woman with true-positive bone metastases. by Jeanette Ansholm Hansen (11726084)

Image_1_Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.tif by Yu Tang (343157)

“…Background<p>After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. …”

Image_2_Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.tif by Yu Tang (343157)

“…Background<p>After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. …”

Table_1_Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.docx by Yu Tang (343157)

“…Background<p>After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. …”

KCNK1 and downstream proteins are positively correlated in clinical breast cancer samples. by Xiangchan Hou (18864991)

Subjects:

Feature selection and significance analysis. by Xin-Ran Zhang (2539957)

Gene sets which were significantly enriched. by Xiangyu Meng (699531)

Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies by Neil A. O'Brien (14989961)

“…Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies…”

Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies by Neil A. O'Brien (14989961)

“…Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies…”

Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies by Neil A. O'Brien (14989961)

“…Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies…”

Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies by Neil A. O'Brien (14989961)

“…Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies…”